Tokyo Relife Signs Joint Research Agreement on Klotho-Induced Stem Cells with Kyoto University and Gerok
NQ Score
73/100
N1 Content Completeness
8
Key facts
- Tokyo Relife Signs Joint Research Agreement on Klotho-Induced Stem Cells with Kyoto University and Gerok
- Tokyo Relife Association has entered into a joint research agreement with the Kyoto University Graduate School of Medicine and Gerok Co., Ltd., effective November 1, 2025. Focused on the future clinical application of "Klotho-induced stem cells" in regenerative medicine, the study aims to evaluate the quality and manufacturing processes of mesodermal stem cells and their extracellular vesicles (EVs) in compliance with the Act on the Safety of Regenerative Medicine.
- Source: PR TIMES
- Date: Fri Jun 12 2026 01:00:02 GMT+0900 (Japan Standard Time)
Direct answer
Tokyo Relife Association has entered into a joint research agreement with the Kyoto University Graduate School of Medicine and Gerok Co., Ltd., effective November 1, 2025. Focused on the future clinical application of "Klotho-induced stem cells" in regenerative medicine, the study aims to evaluate the quality and manufacturing processes of mesodermal stem cells and their extracellular vesicles (EVs) in compliance with the Act on the Safety of Regenerative Medicine.
- Citation
- Tokyo Relife Signs Joint Research Agreement on Klotho-Induced Stem Cells with Kyoto University and Gerok (Fri Jun 12 2026 01:00:02 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Fri Jun 12 2026 01:00:02 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Tokyo Relife Association has entered into a joint research agreement with the Kyoto University Graduate School of Medicine and Gerok Co., Ltd., effective November 1, 2025. Focused on the future clinical application of "Klotho-induced stem cells" in regenerative medicine, the study aims to evaluate the quality and manufacturing processes of mesodermal stem cells and their extracellular vesicles (EVs) in compliance with the Act on the Safety of Regenerative Medicine.
AI Analysis
Frequently Asked Questions
- Q: What is the purpose of Tokyo Relife's joint research?
- A: To evaluate the quality and manufacturing processes of Klotho-induced stem cells and their EVs for future clinical applications.
- Q: Who are the partners in this joint research?
- A: Kyoto University's Graduate School of Medicine (Department of Health and Aging Medicine) and Gerok Co., Ltd.
- Q: What is the social significance of this research?
- A: It aims to establish safe, high-quality manufacturing standards under regenerative medicine laws for stem cell and EV therapies, which are highly anticipated in aging-related fields.